Abstract:Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) mostly driven by the t(15;17) translocation that yields the PML-RARα (PR) fusion protein. Apart from PML, other partner genes have been uncovered to fuse with RARα forming rare X-RARα fusion genes. Among them, TBLR1-RARα (TR) is a novel oncogene to induce APL identified in our previous studies, which elicited differed response and worse prognosis in contrast to the canonical PR fusion gene. Despite the textbook rationale of all-trans retinoid acid (ATRA) and arsenic trioxide (ATO) turning most APL patients with PR fusion gene from highly fatal to highly curable, TR-driven APL did not yield long-term remission both in murine models and patients, highlighting the necessity to dissect the mechanism of drug unresponsiveness and explore novel targeted therapies. In this study, we first established two doxycycline-inducible leukemia cell lines to directly initiate the expression of TR and PR fusion protein in U937 cells, respectively. Transcriptome sequencing analysis showed that interferon (IFN) pathways were significantly suppressed in TR rather than PR-induced leukemia cells. Then we administered IFNs as well as the standard regimen of ATRA and ATO in TR- and PR-induced APL, comparing therapy responses and biological phenotypes with in vitro and in vivo studies. Main results are summarized as follows concerning TR- in comparison to PR-driven APL. Firstly, ATO was unresponsive in TR-induced leukemia cells, which failed to elicit oncoprotein degradation, apoptosis and loss of self-renewal. Secondly, lower doses of ATRA were inadequate. Although a lower dose of ATRA was sufficient to trigger differentiation, increasing doses of ATRA further promoted the degradation of oncoprotein and reduced the colony formation capacity of TR leukemic cells, which ultimately conferred survival benefits in TR mice. Thirdly, type I IFNs was promising, which induced apoptosis, cooperated with ATRA to boost differentiation, and exhibited potential to reduce self-renewal, reflecting anti-leukemia efficacy. Finally, type I IFNs combining with ATRA displayed survival advantage to TR mice, and murine STING agonist DMXAA, which acted upstream to produce type I IFNs, significantly endowed TR mice with extended survival time. Based on our results, we further propose mechanistic hypotheses of TR-APL in comparison with the classic PR-APL. In TR-driven APL, despite the unresponsiveness of ATO, we may utilize STING-IFN pathway agonist to upregulate PML expression, which may obliterate self-renewal independent of ATO response triggered by initial PML nuclear body disruption observed in PR-driven APL, providing therapeutic implications for APL driven by rare RARα fusion genes. Our study aims to gain further understanding of TR-driven APL and integrate insights into principles underlying leukemogenesis mediated by rare RARα fusion genes, which may benefit such a therapy-resistant population and enable APL to be a bona fide curable leukemia.

TRIB3 Promotes APL Progression Through Stabilization of the Oncoprotein PML-RARα and Inhibition of P53-Mediated Senescence.

Data from TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients

RBCK1‐TRIB3 decelerated the progression of acute promyelocytic leukemia

PML-RARα Interaction with TRIB3 Impedes PPARγ/RXR Function and Triggers Dyslipidemia in Acute Promyelocytic Leukemia.

Targeting Pseudokinase TRIB3 Brings about a New Therapeutic Option for Acute Promyelocytic Leukemia

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia Through Ubiquitination and Degradation of PML-RARα

Palmitoyltransferase ZDHHC3 is essential for the oncogenic activity of PML/RARα in acute promyelocytic leukemia

PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα

A Novel Fusion Protein TBLR1-RARα Acts As an Oncogene to Induce Murine Promyelocytic Leukemia: Identification and Treatment Strategies.

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

All -trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells

Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.

PML Mutation in PML-Rarα Alters PML Nuclear Body Organization and Induces ATRA Resistance in Acute Promyelocytic Leukemia

The PML-RARα Fusion Protein and Targeted Therapy for Acute Promyelocytic Leukemia

Targeting Interferon Pathway in TBLR1-RARa-Driven Promyelocytic Leukemia in the Context of ATRA and ATO Unresponsiveness

Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia

8-Cpt-Camp/All-Trans Retinoic Acid Targets T(11;17) Acute Promyelocytic Leukemia Through Enhanced Cell Differentiation And Plzf/Rar Alpha Degradation

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.

Arsenic-induced PML Targeting Onto Nuclear Bodies: Implications for the Treatment of Acute Promyelocytic Leukemia

The transcriptional downregulation of RIAM gene mediated by PML-RARα fusion protein